$ATRA
Atara Biotherapeutics, Inc. Stock $atra

$atra Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000095017025035507 Filed on March 07, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024
Revenue			$128.9M
YoY Change			1404.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$151.5M
YoY Change			-30.88%
% of Gross Profit
Depreciation & Amortization			$2.700M
YoY Change			-44.09%
% of Gross Profit
Operating Expenses			$151.5M
YoY Change			-43.68%
Operating Profit			-$83.44M
YoY Change			-69.01%
Interest Expense			$4.615M
YoY Change			3173.05%
% of Operating Profit
Other Income/Expense, Net			$528.0K
YoY Change			-314.63%
Pretax Income			-$85.42M
YoY Change			-69.06%
Income Tax			-$12.00K
% Of Pretax Income
Net Earnings			-$85.40M
YoY Change			-69.07%
Net Earnings / Revenue			-66.23%
Basic Earnings Per Share			-$11.41
Diluted Earnings Per Share			-$11.41
COMMON SHARES
Basic Shares Outstanding	5.859M	5.760M	7.488M
Diluted Shares Outstanding			7.488M

Balance Sheet

Concept	2025 Q1	2024 Q4	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$25.03M
Short-Term Investments
Other Short-Term Assets		$10.12M
YoY Change		59.79%
Inventory		$10.66M
Prepaid Expenses
Receivables		$1.482M
Other Receivables
Total Short-Term Assets		$64.89M
YoY Change		-36.3%
LONG-TERM ASSETS
Property, Plant & Equipment		$1.294M
YoY Change		-97.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$3.103M
YoY Change		-35.94%
Total Long-Term Assets		$44.20M
YoY Change		-30.54%
TOTAL ASSETS
Total Short-Term Assets		$64.89M
Total Long-Term Assets		$44.20M
Total Assets		$109.1M
YoY Change		-34.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.367M
YoY Change		18.54%
Accrued Expenses		$6.027M
YoY Change		-89.92%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$134.6M
YoY Change		-5.38%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities		$3.269M
YoY Change		-96.28%
Total Long-Term Liabilities		$3.269M
YoY Change		-97.33%
TOTAL LIABILITIES
Total Short-Term Liabilities		$134.6M
Total Long-Term Liabilities		$3.269M
Total Liabilities		$206.4M
YoY Change		-22.04%
SHAREHOLDERS EQUITY
Retained Earnings		-$2.055B
YoY Change		4.34%
Common Stock		$1.957B
YoY Change		4.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$97.28M
YoY Change
Total Liabilities & Shareholders Equity		$109.1M
YoY Change		-34.08%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024
OPERATING ACTIVITIES
Net Income			-$85.40M
YoY Change			-69.07%
Depreciation, Depletion And Amortization			$2.700M
YoY Change			-44.09%
Cash From Operating Activities			-$68.72M
YoY Change			-64.39%
INVESTING ACTIVITIES
Capital Expenditures			$246.0K
YoY Change			-79.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$8.624M
YoY Change			-93.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.348M
YoY Change			337.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			59.28M
YoY Change			2849.35%
NET CHANGE
Cash From Operating Activities			-68.72M
Cash From Investing Activities			8.624M
Cash From Financing Activities			59.28M
Net Change In Cash			-811.0K
YoY Change			-98.79%
FREE CASH FLOW
Cash From Operating Activities			-$68.72M
Capital Expenditures			$246.0K
Free Cash Flow			-$68.96M
YoY Change			-64.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-19000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1043000
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	687000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3130000
CY2024	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-4930000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6140000
CY2024	atra	Increase Decrease In Accrued Research And Development IncreaseDecreaseInAccruedResearchAndDevelopment	-9380000
CY2023	atra	Increase Decrease In Accrued Research And Development IncreaseDecreaseInAccruedResearchAndDevelopment	-3663000
CY2024	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-12504000
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	11064000
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20303000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	30395000
CY2024	atra	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-11051000
CY2023	atra	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-12636000
CY2024	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-462000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	142000
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68717000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-192977000
CY2024	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	19665000
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	83648000
CY2024	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	28535000
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	208712000
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	246000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1223000
CY2024	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8624000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	123866000
CY2024	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-7000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-13000
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59282000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2010000
CY2024	atra	Proceeds From Sale Of Common Stock And Pre Funded Warrants In Registered Direct Offerings Net ProceedsFromSaleOfCommonStockAndPre-FundedWarrantsInRegisteredDirectOfferingsNet	50603000
CY2023	atra	Proceeds From Sale Of Common Stock And Pre Funded Warrants In Registered Direct Offerings Net ProceedsFromSaleOfCommonStockAndPre-FundedWarrantsInRegisteredDirectOfferingsNet	0
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9348000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2136000
CY2024	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	230000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	928000
CY2024	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-811000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-67101000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25987000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93088000
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25176000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25987000
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	132000
CY2024	atra	Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility	0
CY2023	atra	Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility	78000
CY2024	atra	Proceeds From Issuance Of Common Stock Through Atm Facilities Not Yet Received ProceedsFromIssuanceOfCommonStockThroughAtmFacilitiesNotYetReceived	0
CY2023	atra	Proceeds From Issuance Of Common Stock Through Atm Facilities Not Yet Received ProceedsFromIssuanceOfCommonStockThroughAtmFacilitiesNotYetReceived	114000
CY2024	us-gaap	Interest Paid Net InterestPaidNet	685000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	447000
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	24000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q4	atra	Reduction In Current Workforce Percentage ReductionInCurrentWorkforcePercentage	0.30
CY2023Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	6700000
CY2024Q1	atra	Reduction In Current Workforce Percentage ReductionInCurrentWorkforcePercentage	0.25
CY2024Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	5100000
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024	us-gaap	Revenues Revenues	128940000
CY2023	us-gaap	Revenues Revenues	8573000
CY2024	atra	Cost Of Commercialization Revenue CostOfCommercializationRevenue	21009000
CY2023	atra	Cost Of Commercialization Revenue CostOfCommercializationRevenue	8886000
CY2024	atra	Platform Sciences Development And Operations Expense PlatformSciencesDevelopmentAndOperationsExpense	-77444000
CY2023	atra	Platform Sciences Development And Operations Expense PlatformSciencesDevelopmentAndOperationsExpense	-122940000
CY2024	atra	Medical And Safety Expense MedicalAndSafetyExpense	-44138000
CY2023	atra	Medical And Safety Expense MedicalAndSafetyExpense	-67445000
CY2024	atra	Regulatory And Quality Expense RegulatoryAndQualityExpense	-29901000
CY2023	atra	Regulatory And Quality Expense RegulatoryAndQualityExpense	-34400000
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39886000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50908000
CY2024	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1965000
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	120000
CY2024	us-gaap	Profit Loss ProfitLoss	-85403000
CY2023	us-gaap	Profit Loss ProfitLoss	-276126000
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We prepare our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Significant estimates and assumptions relied upon in preparing these financial statements include those related to revenue recognition, accrued research and development expenses, stock-based compensation expense, liability related to the sale of future revenues and income taxes. Additionally, we use available market information to assess the fair value of our short-term investments. Actual results could differ materially from those estimates. If actual amounts differ from estimates, we include the updates in our consolidated results of operations in the period the actual amounts become known. Historically, the aggregate differences, if any, between our estimates and actual amounts in any year have not had a material effect on our consolidated financial statements.</span></p>
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001604464
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2012-08-01
CY2024	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2024#CostsAndExpenses
CY2023	us-gaap	Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2024#CostsAndExpenses
CY2024Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2024Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-36548
CY2024	dei	Entity Registrant Name EntityRegistrantName	ATARA BIOTHERAPEUTICS, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-0920988
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	1280 Rancho Conejo Blvd
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Thousand Oaks
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91320
CY2024	dei	City Area Code CityAreaCode	805
CY2024	dei	Local Phone Number LocalPhoneNumber	623-4211
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024	dei	Trading Symbol TradingSymbol	ATRA
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	41039683
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5858909
CY2024	cyd	Cybersecurity Risk Management Processes Integrated Flag CybersecurityRiskManagementProcessesIntegratedFlag	true
CY2024	cyd	Cybersecurity Risk Management Third Party Engaged Flag CybersecurityRiskManagementThirdPartyEngagedFlag	true
CY2024	cyd	Cybersecurity Risk Third Party Oversight And Identification Processes Flag CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag	true
CY2024	cyd	Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag	false
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	34
CY2024	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2024	dei	Auditor Location AuditorLocation	San Francisco, California
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25030000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25841000
CY2024Q4	us-gaap	Short Term Investments ShortTermInvestments	17466000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	25884000
CY2024Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	146000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	146000
CY2024Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1482000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34108000
CY2024Q4	us-gaap	Inventory Net InventoryNet	10655000
CY2023Q4	us-gaap	Inventory Net InventoryNet	9706000
CY2024Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10115000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6184000
CY2024Q4	us-gaap	Assets Current AssetsCurrent	64894000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	101869000
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1294000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3856000
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39807000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	54935000
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3103000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4844000
CY2024Q4	us-gaap	Assets Assets	109098000
CY2023Q4	us-gaap	Assets Assets	165504000
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4367000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3684000
CY2024Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6589000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11519000
CY2024Q4	atra	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7984000
CY2023Q4	atra	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	17364000
CY2024Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	95092000
CY2023Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	77833000
CY2024Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20542000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	31826000
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	134574000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142226000
CY2024Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	37562000
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29914000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45693000
CY2024Q4	atra	Liability Related To The Sale Of Future Royalties Long Term LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm	38624000
CY2023Q4	atra	Liability Related To The Sale Of Future Royalties Long Term LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm	34623000
CY2024Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3269000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4631000
CY2024Q4	us-gaap	Liabilities Liabilities	206381000
CY2023Q4	us-gaap	Liabilities Liabilities	264735000
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5859000
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5859000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4258000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4258000
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2024Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1957261000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1870123000
CY2024Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-204000
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2054553000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1969150000
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	-97283000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-99231000
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109098000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165504000
CY2024	atra	Commercialization Revenue CommercializationRevenue	128940000
CY2023	atra	Commercialization Revenue CommercializationRevenue	7886000
CY2024	atra	License And Collaboration Revenue LicenseAndCollaborationRevenue	0
CY2023	atra	License And Collaboration Revenue LicenseAndCollaborationRevenue	687000
CY2024	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	128940000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8573000
CY2024	atra	Cost Of Commercialization Revenue CostOfCommercializationRevenue	21009000
CY2023	atra	Cost Of Commercialization Revenue CostOfCommercializationRevenue	8886000
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	151483000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	224785000
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	39886000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50908000
CY2024	us-gaap	Costs And Expenses CostsAndExpenses	212378000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	284579000
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-83438000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-276006000
CY2024	us-gaap	Interest Income Operating InterestIncomeOperating	2110000
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	5426000
CY2024	us-gaap	Interest Expense InterestExpense	4615000
CY2023	us-gaap	Interest Expense InterestExpense	5285000
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	528000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-246000
CY2024	atra	Total Other Income Expense Net TotalOtherIncomeExpenseNet	-1977000
CY2023	atra	Total Other Income Expense Net TotalOtherIncomeExpenseNet	-105000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85415000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-276111000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-85403000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-276126000
CY2024	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	212000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1863000
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85191000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	94000
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	892000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	947000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-274263000
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.41
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.41
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-65.19
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-65.19
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7488000
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7488000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4236000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4236000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126640000
CY2023	atra	Issuance Of Common Stock Net Of Commissions And Offering Costs Value IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue	2172000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	94000
CY2023	atra	Issuance Of Common Stock Pursuant To Employee Stock Awards Value IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue	928000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45386000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-276126000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1863000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-99231000
CY2024	atra	Issuance Of Pre Funded Warrants Net Of Offering Costs IssuanceOfPreFundedWarrantsNetOfOfferingCosts	397000
CY2024	atra	Issuance Of Pre Funded Warrants Registered Direct Offering Value IssuanceOfPreFundedWarrantsRegisteredDirectOfferingValue	50603000
CY2024	atra	Issuance Of Common Stock Net Of Commissions And Offering Costs Value IssuanceOfCommonStockNetOfCommissionsAndOfferingCostsValue	9312000
CY2024	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	7000
CY2024	atra	Issuance Of Common Stock Pursuant To Employee Stock Awards Value IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue	230000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27001000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-85403000
CY2024	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	212000
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	-97283000
CY2024	us-gaap	Profit Loss ProfitLoss	-85403000
CY2023	us-gaap	Profit Loss ProfitLoss	-276126000
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	27001000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	45386000
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5051000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4829000
CY2024	us-gaap	Accretion Expense AccretionExpense	4109000
CY2023	us-gaap	Accretion Expense AccretionExpense	4792000
CY2024	atra	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	12126000
CY2023	atra	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	11795000
CY2024	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	240000
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-792000
CY2024	atra	Other Non Cash Items Net OtherNonCashItemsNet	-402000
CY2023	atra	Other Non Cash Items Net OtherNonCashItemsNet	214000
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-32626000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6113000
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4434000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8120000
CY2024	atra	Increase Decrease In Other Current Asset IncreaseDecreaseInOtherCurrentAsset	1227000
CY2023	atra	Increase Decrease In Other Current Asset IncreaseDecreaseInOtherCurrentAsset	-273000
CY2024	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25
CY2024	atra	Going Concern Policy Textblock GoingConcernPolicyTextblock	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred operating losses since inception and we expect that existing cash, cash equivalents and short-term investments as of December 31, 2024, will not be sufficient to fund our planned operations for at least 12 months after the issuance of the accompanying consolidated financial statements. Although we anticipate the receipt of certain payments from the amended and restated Pierre Fabre Commercialization Agreement, such payments are contingent upon the successful filing and approval of the tab-cel BLA, as well as the completion of specific development and regulatory activities by us and actions taken by third parties, and are, therefore, uncertain at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to secure additional capital, potentially through a combination of public or private security offerings; use of our ATM facility as described in Note 10; and/or strategic transactions. We may need to raise additional funding as required based on the status of our development programs and our projected cash flows. Although we have been successful in raising capital in the past, and expect to continue to raise capital as required, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If we are unable to obtain sufficient funding on acceptable terms, we could be forced to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates, which could have a material adverse effect on our business, results of operations, and financial condition. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern for at least 12 months after the issuance of the accompanying consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk and Other Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, the amount of which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also make short-term investments in money market funds; U.S. Treasury, government agency and corporate debt obligations; commercial paper; certificates of deposit; and asset-backed securities, which can be subject to certain credit risk. We strive to mitigate this credit risk by investing in high-grade instruments, limiting our exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers.</span></p>
CY2024	atra	Cash And Cash Equivalents Maturity Period CashAndCashEquivalentsMaturityPeriod	P90D
CY2024	atra	Investment Maturity Period InvestmentMaturityPeriod	P90D
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	401(k)
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2024	atra	Defined Contribution Plan Contributions By Employer DefinedContributionPlanContributionsByEmployer	1200000
CY2023	atra	Defined Contribution Plan Contributions By Employer DefinedContributionPlanContributionsByEmployer	1900000
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	642774000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	686149000
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	41168000
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	41176000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	50393000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	50189000
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0
CY2024Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	41168000
CY2024Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	41176000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	50393000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	50189000
CY2024	atra	Write Off Of Accrued Interest Receivable WriteOffOfAccruedInterestReceivable	0
CY2023	atra	Write Off Of Accrued Interest Receivable WriteOffOfAccruedInterestReceivable	0
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25030000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25841000
CY2024Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	146000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	146000
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25176000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25987000
CY2024	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	45700000
CY2024	atra	Revenue Recognition Performance Satisfied Or Partially Satisfied Prior Period RevenueRecognitionPerformanceSatisfiedOrPartiallySatisfiedPriorPeriod	900000
CY2023Q4	atra	Liability Related To The Sale Of Future Royalties LiabilityRelatedToTheSaleOfFutureRoyalties	35076000
CY2024	us-gaap	Accretion Expense AccretionExpense	4109000
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	67000
CY2024	us-gaap	Payments For Royalties PaymentsForRoyalties	246000
CY2024Q4	atra	Liability Related To The Sale Of Future Royalties LiabilityRelatedToTheSaleOfFutureRoyalties	39006000
CY2024Q4	atra	Liability Related To The Sale Of Future Revenue Current LiabilityRelatedToTheSaleOfFutureRevenueCurrent	-382000
CY2024Q4	atra	Liability Related To The Sale Of Future Royalties Long Term LiabilityRelatedToTheSaleOfFutureRoyaltiesLongTerm	38624000
CY2021Q1	atra	Lease Option To Extend Additional Term LeaseOptionToExtendAdditionalTerm	P5Y
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17004000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1263000
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15677000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1285000
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5494000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	437000
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3319000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3415000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9044000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	53953000
CY2024Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2985000
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11160000
CY2024Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	346000
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	42793000
CY2024Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2639000
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12879000
CY2024Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1038000
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29914000
CY2024Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2024Q4	atra	Operating Lease Other Long Term Liabilities OperatingLeaseOtherLongTermLiabilities	0
CY2024Q4	atra	Finance Lease Other Long Term Liabilities FinanceLeaseOtherLongTermLiabilities	1601000
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	42793000
CY2024Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2639000
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	16930000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	17192000
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	193000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	201000
CY2024	atra	Operating Lease Cost Including Short Term Lease OperatingLeaseCostIncludingShortTermLease	17123000
CY2023	atra	Operating Lease Cost Including Short Term Lease OperatingLeaseCostIncludingShortTermLease	17393000
CY2024	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	959000
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	976000
CY2024	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	326000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	416000
CY2024	atra	Finance Lease Cost FinanceLeaseCost	1285000
CY2023	atra	Finance Lease Cost FinanceLeaseCost	1392000
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	16019000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	16660000
CY2024	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	326000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	416000
CY2024	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	892000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	947000
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	312000
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2024	atra	Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities	-3002000
CY2023	atra	Non Cash Increase To Operating Lease Assets Due To Remeasurement Of Lease Liabilities NonCashIncreaseToOperatingLeaseAssetsDueToRemeasurementOfLeaseLiabilities	-1589000
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2024Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.112
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.114
CY2024Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.104
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.104
CY2022Q3	atra	Reduction In Current Workforce Percentage ReductionInCurrentWorkforcePercentage	0.20
CY2022Q3	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	6000000
CY2023Q4	atra	Reduction In Current Workforce Percentage ReductionInCurrentWorkforcePercentage	0.30
CY2023Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	6700000
CY2024Q1	atra	Reduction In Current Workforce Percentage ReductionInCurrentWorkforcePercentage	0.25
CY2024Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	5100000
CY2024Q4	atra	Restructuring Liability Jan2024 RestructuringLiabilityJan2024	100000
CY2024	us-gaap	Restructuring Charges RestructuringCharges	5107000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	6730000
CY2024Q4	atra	Accrued Expense Restructuring AccruedExpenseRestructuring	100000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	4923000
CY2022Q4	us-gaap	Restructuring Reserve RestructuringReserve	1545000
CY2024	us-gaap	Restructuring Charges RestructuringCharges	5107000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	6730000
CY2024	us-gaap	Payments For Restructuring PaymentsForRestructuring	9298000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	3352000
CY2024	atra	Non Cash Settlements NonCashSettlements	-669000
CY2023	atra	Non Cash Settlements NonCashSettlements	0
CY2024Q4	us-gaap	Restructuring Reserve RestructuringReserve	63000
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	4923000
CY2024Q4	atra	Contractual Obligations Due To Licensors ContractualObligationsDueToLicensors	0
CY2023Q4	atra	Contractual Obligations Due To Licensors ContractualObligationsDueToLicensors	0
CY2024Q4	atra	Accrued Termination Charges AccruedTerminationCharges	0
CY2023Q4	atra	Accrued Termination Charges AccruedTerminationCharges	0
CY2024Q4	atra	Recorded Unconditional Service Obligations Due Within One Year RecordedUnconditionalServiceObligationsDueWithinOneYear	13308000
CY2024Q4	atra	Recorded Unconditional Service Obligation Due In Second Year RecordedUnconditionalServiceObligationDueInSecondYear	9605000
CY2024Q4	atra	Recorded Unconditional Service Obligations Due Within Third Year RecordedUnconditionalServiceObligationsDueWithinThirdYear	3388000
CY2024Q4	atra	Recorded Unconditional Service Obligation RecordedUnconditionalServiceObligation	26301000
CY2024	atra	Minimum Commitments Expense MinimumCommitmentsExpense	14100000
CY2023	atra	Minimum Commitments Expense MinimumCommitmentsExpense	19400000
CY2024Q4	atra	Minimum Purchase Commitments Accrued MinimumPurchaseCommitmentsAccrued	5300000
CY2023Q4	atra	Minimum Purchase Commitments Accrued MinimumPurchaseCommitmentsAccrued	11200000
CY2024Q4	atra	Liabilities Related To Indemnification Agreements LiabilitiesRelatedToIndemnificationAgreements	0
CY2023Q4	atra	Liabilities Related To Indemnification Agreements LiabilitiesRelatedToIndemnificationAgreements	0
CY2024Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	520000000
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	758900
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8.25
CY2024Q4	atra	Common Stock Value Remained Available To Be Sold CommonStockValueRemainedAvailableToBeSold	88700000
CY2024	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	0
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.142
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.839
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.042
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.2
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	65.5
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	16500
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	187756
CY2024	atra	Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue	151800
CY2023	atra	Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue	12298010
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9000000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	17000000
CY2024Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1142149
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27001000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45386000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-85311000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-276360000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-104000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	249000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85415000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-276111000
CY2024	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000
CY2024	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-12000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14000
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	15000
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.268
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.043
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.162
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.045
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.233
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.204
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	259376000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	323581000
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	61113000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	72229000
CY2024Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	8216000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	30580000
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5789000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14033000
CY2024Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	14709000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	17018000
CY2024Q4	atra	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	9403000
CY2023Q4	atra	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	12035000
CY2024Q4	atra	Deferred Tax Assets License Fees DeferredTaxAssetsLicenseFees	4794000
CY2023Q4	atra	Deferred Tax Assets License Fees DeferredTaxAssetsLicenseFees	5926000
CY2024Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13748000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11187000
CY2024Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	377148000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	486589000
CY2024Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	368401000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	474982000
CY2024Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8747000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11607000
CY2024Q4	atra	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	8747000
CY2023Q4	atra	Deferred Tax Liabilities Operating Lease Assets DeferredTaxLiabilitiesOperatingLeaseAssets	11607000
CY2024Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	8747000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11607000
CY2024Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2024	atra	Deferred Tax Assets Change In Capitalized Expenses Amount DeferredTaxAssetsChangeInCapitalizedExpensesAmount	11100000
CY2023	atra	Deferred Tax Assets Change In Capitalized Expenses Amount DeferredTaxAssetsChangeInCapitalizedExpensesAmount	21700000
CY2024	atra	Tax Credit Carryforward Change In Amount TaxCreditCarryforwardChangeInAmount	22400000
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	106600000
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	1200000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	150965000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5538000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3843000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	160346000
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1011000
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	647000
CY2024	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	124071000
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	37933000
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2024Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	964000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2335000
CY2024Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9691000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	7371000
CY2024Q4	us-gaap	Inventory Net InventoryNet	10655000
CY2023Q4	us-gaap	Inventory Net InventoryNet	9706000
CY2024Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18601000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19725000
CY2024Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17307000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15869000
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1294000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3856000
CY2024	us-gaap	Depreciation Depreciation	2700000
CY2023	us-gaap	Depreciation Depreciation	3700000
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6027000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19007000
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12879000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11264000
CY2024Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1038000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	915000
CY2024Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	598000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	640000
CY2024Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	20542000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	31826000
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-25-035507-index-headers.html	Edgar Link	pending
0000950170-25-035507-index.html	Edgar Link	pending
0000950170-25-035507.txt	Edgar Link	pending
0000950170-25-035507-xbrl.zip	Edgar Link	pending
atra-20241231.htm	Edgar Link	pending
atra-20241231.xsd	Edgar Link	pending
atra-ex19_1.htm	Edgar Link	pending
atra-ex21_1.htm	Edgar Link	pending
atra-ex23_1.htm	Edgar Link	pending
atra-ex31_1.htm	Edgar Link	pending
atra-ex31_2.htm	Edgar Link	pending
atra-ex32_1.htm	Edgar Link	pending
atra-ex4_6.htm	Edgar Link	pending
atra-ex97_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img121855242_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
atra-20241231_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATRA
Atara Biotherapeutics, Inc. Stock $atra

2025 Q1 Form 10-K Financial Statement

#000095017025035507 Filed on March 07, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATRA Atara Biotherapeutics, Inc. Stock $atra

2025 Q1 Form 10-K Financial Statement

#000095017025035507 Filed on March 07, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATRA
Atara Biotherapeutics, Inc. Stock $atra